Alnylam Pharmaceuticals, Inc. (ALNY)

Nasdaq · Cambridge, Massachusetts, USA · Founded 2002 · CEO Yvonne Greenstreet

Valuation summary

$183.53 fair value versus $147.82 in the market, a difference of +24.2%. Rated Buy.

Fair value per share$183.53
Current share price$147.82
Upside / downside+24.2%
Bear case$115.96
Bull case$279.97
Discount rate (WACC)10.4%
Terminal growth3.50%
Market capitalisation$20B
EV / Sales4.3x

About Alnylam Pharmaceuticals, Inc.

Founded in 2002 to turn RNA interference, a Nobel Prize-winning discovery, into medicines. Yvonne Greenstreet has been chief executive since 2022. RNAi drugs silence the gene that produces a harmful protein, often with injections only a few times a year. Alnylam's largest product, Amvuttra, was approved in 2025 to treat ATTR amyloidosis with cardiomyopathy, a large heart disease market, which has driven very fast sales growth and pushed the company into profitability.

Investment case

  • Amvuttra's cardiomyopathy launch is one of the strongest in biotech.
  • A platform that has produced several approved drugs, with more in the pipeline, including for hypertension.
  • Turning profitable, with margins set to rise quickly.

Key risks

  • Competition in ATTR cardiomyopathy from Pfizer's tafamidis and BridgeBio's acoramidis.
  • Heavy reliance on one drug family.
  • Drug pricing reform could affect high-priced rare disease medicines.

Recent developments

Revenue by segment

TTR franchise (Amvuttra, Onpattro)75%
Rare disease products15%
Collaborations & royalties10%

Five-year forecast

RevenueFree cash flow
Year 1$7.0B$0.7B
Year 2$9.6B$1.0B
Year 3$12.2B$1.4B
Year 4$14.4B$1.7B
Year 5$15.8B$1.9B

What the street says

Viewed as one of the few large biotechs with a long growth runway; the debate is market share in cardiomyopathy.

Comparable companies: NTRA · TEM · DXCM · HIMS · ARGX · HUM · GEHC · BSX

Open the interactive model, price chart and sensitivity grid →